---
title: Magnetic stimulation slows Parkinson progression
nct_id: NCT06002581
phase: NA
status: RECRUITING
sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06002581"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06002581"
last_fetched: "2026-05-10T14:02:52.716Z"
source: "Parkinson's Pathways (curated)"
---
# Magnetic stimulation slows Parkinson progression

**Goal (in five words):** Magnetic stimulation slows Parkinson progression

**Official Title:** Clinical Study on the Efficacy and Safety of rTMS Regulating Slow-wave Sleep to Delay the Progression of Parkinson's Disease

**Trial ID:** [NCT06002581](https://clinicaltrials.gov/study/NCT06002581)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Target Enrollment:** 56 participants
- **Start Date:** 2023-09-03
- **Completion Date:** 2026-07-28
- **Conditions:** Parkinson's Disease
- **Interventions:** rTMS real stimulation stage1, rTMS shame stimulation stage1, rTMS real stimulation stage 2
- **Intervention Types:** DEVICE

## Summary For Families

Goal: The trial aims to slow Parkinson's progression by boosting deep slow-wave sleep, which may help the brain clear toxic proteins and support repair and plasticity linked to symptom worsening. Approach: It uses repetitive transcranial magnetic stimulation, noninvasive magnetic pulses to targeted brain regions to increase slow-wave non-REM sleep; rTMS does not change levodopa itself, so participants keep a stable levodopa dose while researchers test whether better slow-wave sleep affects symptoms or disease course. Eligibility: The study is enrolling right-handed Chinese Han adults aged 50 to 80 with clinically probable or definite PD at Hoehn-Yahr stages 1,4, on a stable levodopa regimen, without major cognitive impairment, prior brain surgery or TMS, significant sleep apnea or other listed contraindications.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Meet the clinically definite or clinically probable PD according to the MDS 2015 version.
2. Chinese Han population (three generations), age greater than or equal to 50 years old, less than or equal to 80 years old, male or female.
3. Hoehn-Yahr stages 1-4.
4. The dose of levodopa drug therapy was stable three weeks before enrollment and during the follow-up period.
5. Right-handed.
6. The patient signed a written informed consent.

Exclusion Criteria:

1. Any form of Parkinsonism other than primary PD.
2. Those who have received neurosurgical intervention or stereotaxic brain surgery for PD, or have previously received TMS treatment.
3. Cognitive dysfunction (MMSE ≤ 24 points) or those who cannot cooperate with the scale score.
4. Persons with mental disabilities.
5. Pregnant women.
6. There are contraindications for rTMS treatment.
7. There are contraindications for MRI examination.
8. Baseline PSG suggests other sleep disorders such as moderate to severe OSAS; BMI\>=30.
9. Patients who are addicted to alcohol, taking SSRIs, TCAs, sedative hypnotics, histamine antagonists and other drugs and food that may affect NREM and REM sleep structure.
10. Those who are unwilling to participate in the study or unable to sign the informed consent form; and other circumstances that the researcher considers inappropriate to participate in the study.

    \-
```

## Locations (1)

- Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China _(31.2222, 121.4581)_
  - Xiaoying Zhu, MD — (CONTACT) — +86 13817659260 — docxiaoying@163.com

## Central Contacts

- Xiaoying Zhu, doctor — (CONTACT) — +86 21 63240090 — docxiaoying@163.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06002581*  
*HTML version: https://parkinsonspathways.com/trial/NCT06002581*  
*Source data: https://clinicaltrials.gov/study/NCT06002581*